R&D Trends

Sangamo BioSciences, City of Hope granted $5.6M from CIRM

Friday, May 30, 2014 01:36 PM

The California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP therapeutic for HIV/AIDS based on the application of SangamoBioSciences' zinc finger nuclease (ZFN) genome-editing technology in hematopoietic stem/progenitor cells (HSPCs).

More... »

WIRB Copernicus Group

Agenda-setting plan issued to accelerate cancer research, biomedical discovery

Friday, May 30, 2014 01:34 PM

The National Patient Advocate Foundation (NPAF), a nonprofit organization providing the patient's voice in improving access to quality cancer care, has released a blueprint to accelerate the delivery of new treatments to patients and launched a new grassroots movement called Project Innovation to drive action.

More... »

CRF Health eCOA webinar series

Oncothyreon, Celldex Therapeutics collaborate

Thursday, May 29, 2014 01:03 PM

Oncothyreon, a biotechnology company developing therapeutic products for the treatment of cancer, and Celldex Therapeutics have agreed to collaborate on a combined clinical trial of ONT-10 and varlilumab.

More... »

The Michael J. Fox Foundation, AbbVie launch Partners in Parkinson's

Wednesday, May 28, 2014 01:06 PM

The Michael J. Fox Foundation (MJFF) and AbbViehave launched Partners in Parkinson's, a new strategic health initiative offering comprehensive support to help people with Parkinson's disease (PD) optimize their care at every stage of the disease.

More... »

Macrogenics, Takeda ink agreement for autoimmune disorders

Wednesday, May 28, 2014 01:04 PM

MacroGenics, a clinical-stage biopharmaceutical company discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, and Takeda Pharmaceutical have entered into an agreement for the development and commercialization of MGD010.

More... »

Bristol-Myers Squibb collaborates with CytomX Therapeutics, Incyte

Wednesday, May 28, 2014 01:01 PM

Bristol-Myers Squibb has formed two separate collaboration agreements. BMS and CytomX Therapeutics are collaborating on novel therapies against multiple immuno-oncology targets using CytomX’s proprietary Probody Platform. BMS and Incyte, a Wilmington, Del.-based biopharmaceutical company, have established a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of BMS’ investigational PD-1 immune checkpoint inhibitor nivolumab and Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor INCB24360, in a phase I/II study.

More... »

Report: Turkish manufacturers boost growth, niche products, biologics development

Wednesday, May 28, 2014 12:54 PM

CPhI Worldwide’s Pharma Insights report on Turkey shows Turkish manufacturers moving beyond domestic market export has led to growth, niche products and biologics development. The comprehensive analysis of the Turkish pharma market was conducted among all major Turkish manufacturers, evaluating conditions for both foreign and domestic companies, and was compiled with the help of research partner Global Business Reports.

More... »

Celerion, Korean Drug Development Fund collaborate on early phase clinical research

Wednesday, May 28, 2014 12:52 PM

Celerion and the Korean Drug Development Fund (KDDF) are collaborating to provide drug development experience and support for South Korea’s emerging drug discovery and development industry. 

More... »

NIA/NIH grants $1.4M to Cognition Therapeutics' Alzheimer's program

Friday, May 23, 2014 02:35 PM

Cognition Therapeutics, an innovative research and drug discovery organization focused on the development of novel disease-modifying therapeutics for neurodegenerative diseases, has announced that its small molecule soluble Abeta receptor antagonist program for the treatment of Alzheimer's disease (AD) has been selected for funding by the National Institute on Aging (NIA)/NIH Alzheimer's Disease Drug Development Program. This cooperative agreement program for Alzheimer's disease translational research will provide Cognition Therapeutics with an estimated $1.4M in funding over four years to support critical drug development activities aimed at securing IND status for the company's first-in-class therapeutics.

More... »

BioRestorative Therapies, Pfizer ink research agreement

Friday, May 23, 2014 10:30 AM

BioRestorative Therapies, a life sciences company focused on adult stem cell-based therapies for various personal medical applications, has entered into a two-year collaborative research agreement with Pfizer to study human brown adipose tissue and cell lines.

More... »

Subscribe to The CenterWatch Monthly



Browse by:


July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs